<DOC>
	<DOCNO>NCT02428231</DOCNO>
	<brief_summary>The primary objective study ass whether 6-week titration ( compare 1-week titration ) effective reduce incidence dimethyl fumarate ( DMF ) -related gastrointestinal ( GI ) Adverse Events ( AEs ) subject Multiple Sclerosis ( MS ) . The secondary objective study ass whether 6-week titration ( compare 1-week titration ) effective reduce average severity duration GI symptoms 12 week dimethyl fumarate treatment study population .</brief_summary>
	<brief_title>Tecfidera Slow-titration Study</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Diagnosis MS consistent locally label indication dimethyl fumarate No prior treatment dimethyl fumarate Female subject childbearing potential surgically sterile must practice effective contraception participation study Have recent complete blood count ( CBC ) , include lymphocyte count , preclude participation study Key Have recent history ongoing GI illness ( e.g. , peptic ulcer , irritable bowel syndrome ) current condition GI sign symptom ( e.g. , nausea , vomit , abdominal pain , diarrhea ) may interfere assessment study endpoint Have comorbid condition preclude participation study Participant pregnant , breastfeeding , plan pregnancy study period Are receive concomitant diseasemodifying therapy MS include , limited , natalizumab , IFNÎ² , glatiramer acetate , fingolimod , alemtuzumab , teriflunomide , laquinimod screen History severe allergic anaphylactic reaction know drug hypersensitivity NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>